Boustead Singapore Limited has acquired a 60% stake in UroMedTech Pte Ltd through a S$6 million equity investment, expanding its healthcare technology portfolio.
UroMedTech develops the UroMaster robotic platform for prostate cancer diagnosis, which is approved in Singapore, Malaysia, Australia, and other Asian markets and is deployed across seven hospitals and clinical sites. The company is also developing AI-assisted pathology and focal therapy capabilities to create an integrated prostate cancer diagnosis and treatment platform.
Related: Vivani to sell neurotech subsidiary Cortigent to ClearOne
The investment will support commercialization of UroMaster, expansion into international markets, continued R&D, and regulatory approvals in the U.S. and Europe.
Founder and CEO Dr. Wilson Gao said:
“Joining the Boustead family marks a new chapter for UroMedTech. BMCH shares our commitment to healthcare innovation and patient-centered care, and together we hope to accelerate its development and clinical adoption.”
The acquisition strengthens Boustead’s presence in precision urology and AI-enabled medical robotics while supporting UroMedTech’s global expansion strategy.
